Literature DB >> 18812208

Relative involvement of three 17beta-hydroxysteroid dehydrogenases (types 1, 7 and 12) in the formation of estradiol in various breast cancer cell lines using selective inhibitors.

Yannick Laplante1, Claudine Rancourt, Donald Poirier.   

Abstract

We investigated the relative involvement of three reductive 17beta-hydroxysteroid dehydrogenase (17beta-HSD) isoforms, namely types 1, 7 and 12, in the formation of potent estrogen estradiol (E2) in 10 human breast cancer cell lines (T-47D, MCF-7, ZR-75-1, CAMA-1, BT-20, BRC-17, BRC-31, BRC-32, BRC-36 and BRN-196) and also in 1 choriocarcinoma cell line (JEG-3) using selective inhibitors. In T-47D, BT-20 and JEG-3 cells, a 17beta-HSD1 inhibitor almost completely inhibited the formation of E2 at 1microM from 60nM of estrone (E1) (98%, 91% and 90%, respectively), whereas no significant inhibition of E2 formation was obtained using inhibitors of types 7 and 12. However, we obtained lower levels of inhibition (32%, 36% and 35% respectively using inhibitors of types 1, 7 and 12 at 10microM) in MCF-7 cells and even lower and variable levels of inhibition (15%, 23% and 18% respectively using inhibitors of types 1, 7 and 12 at 10microM) in ZR-75-1 cells. No inhibition of E2 formation was observed in CAMA-1 cells with a 17beta-HSD1 inhibitor at 1microM whereas inhibitors of types 7 and 12 inhibited 40% and 30% of E2 formation, respectively. In BRC and BRN cell lines, types 1, 7 and 12 17beta-HSDs were all involved in the formation of E2, but type 12 seemed to predominate. At 10microM, each inhibitor inhibited 10-50% of the formation of E2. Using MCF-7 and BRC-32 cell lines, a combination of the three inhibitors (3x10microM) does not fully inhibit the 17beta-HSD activity (65% and 75%). In addition to identify the relative importance of types 1, 7 and 12 17beta-HSDs in the formation of E2 in human breast cancer cell lines, our results show also a great variability between each cell line. In some cases the formation of E2 was completely inhibited, but this was not the result observed in other cell lines, suggesting the presence of another enzyme involved in the biosynthesis of E2.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18812208     DOI: 10.1016/j.mce.2008.08.026

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  15 in total

1.  Inhibitory effects of calcitriol on the growth of MCF-7 breast cancer xenografts in nude mice: selective modulation of aromatase expression in vivo.

Authors:  Srilatha Swami; Aruna V Krishnan; Jennifer Y Wang; Kristin Jensen; Lihong Peng; Megan A Albertelli; David Feldman
Journal:  Horm Cancer       Date:  2011-06       Impact factor: 3.869

2.  The stimulation of HSD17B7 expression by estradiol provides a powerful feed-forward mechanism for estradiol biosynthesis in breast cancer cells.

Authors:  Aurora Shehu; Constance Albarracin; Y Sangeeta Devi; Kristin Luther; Julia Halperin; Jamie Le; Jifang Mao; Rachel W Duan; Jonna Frasor; Geula Gibori
Journal:  Mol Endocrinol       Date:  2011-03-03

3.  Synergistic control of sex hormones by 17β-HSD type 7: a novel target for estrogen-dependent breast cancer.

Authors:  Xiaoqiang Wang; Catherine Gérard; Jean-François Thériault; Donald Poirier; Charles J Doillon; Sheng-Xiang Lin
Journal:  J Mol Cell Biol       Date:  2015-05-12       Impact factor: 6.216

Review 4.  Intracrine Regulation of Estrogen and Other Sex Steroid Levels in Endometrium and Non-gynecological Tissues; Pathology, Physiology, and Drug Discovery.

Authors:  Gonda Konings; Linda Brentjens; Bert Delvoux; Tero Linnanen; Karlijn Cornel; Pasi Koskimies; Marlies Bongers; Roy Kruitwagen; Sofia Xanthoulea; Andrea Romano
Journal:  Front Pharmacol       Date:  2018-09-19       Impact factor: 5.810

5.  Novel hydroxysteroid (17beta) dehydrogenase 1 inhibitors reverse estrogen-induced endometrial hyperplasia in transgenic mice.

Authors:  Taija Saloniemi; Päivi Järvensivu; Pasi Koskimies; Heli Jokela; Tarja Lamminen; Sadaf Ghaem-Maghami; Roberto Dina; Pauliina Damdimopoulou; Sari Mäkelä; Antti Perheentupa; Harry Kujari; Jan Brosens; Matti Poutanen
Journal:  Am J Pathol       Date:  2010-01-21       Impact factor: 4.307

6.  Aldo-keto reductase 1C3 expression in MCF-7 cells reveals roles in steroid hormone and prostaglandin metabolism that may explain its over-expression in breast cancer.

Authors:  Michael C Byrns; Ling Duan; Seon Hwa Lee; Ian A Blair; Trevor M Penning
Journal:  J Steroid Biochem Mol Biol       Date:  2009-12-28       Impact factor: 4.292

7.  17beta-hydroxysteroid dehydrogenase type 1 modulates breast cancer protein profile and impacts cell migration.

Authors:  Juliette A Aka; Mouna Zerradi; François Houle; Jacques Huot; Sheng-Xiang Lin
Journal:  Breast Cancer Res       Date:  2012-06-12       Impact factor: 6.466

8.  Crucial Role of 3-Bromoethyl in Removing the Estrogenic Activity of 17β-HSD1 Inhibitor 16β-(m-Carbamoylbenzyl)estradiol.

Authors:  René Maltais; Diana Ayan; Donald Poirier
Journal:  ACS Med Chem Lett       Date:  2011-07-17       Impact factor: 4.345

9.  The contribution of 17beta-hydroxysteroid dehydrogenase type 1 to the estradiol-estrone ratio in estrogen-sensitive breast cancer cells.

Authors:  Chen-Yan Zhang; Jiong Chen; Da-Chuan Yin; Sheng-Xiang Lin
Journal:  PLoS One       Date:  2012-01-09       Impact factor: 3.240

10.  Lyn modulates Claudin-2 expression and is a therapeutic target for breast cancer liver metastasis.

Authors:  Sébastien Tabariès; Matthew G Annis; Brian E Hsu; Christine E Tam; Paul Savage; Morag Park; Peter M Siegel
Journal:  Oncotarget       Date:  2015-04-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.